Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
View Top Employees from Cara TherapeuticsWebsite | http://www.caratherapeutics.com |
Ticker | CARA |
Revenue | $13 million |
Funding | $55 million |
Employees | 107 (107 on RocketReach) |
Founded | 2004 |
Address | 4 Stamford Plaza 9th Floor, Stamford, Connecticut 06902, US |
Phone | (203) 406-3700 |
Technologies |
JavaScript,
HTML,
PHP
+28 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Therapeutics |
Web Rank | 2 Million |
Keywords | Cara Therapeutics, Caratherapeutics.Com Earnings, Non-Opioid Analgesics For Acute Pain, Cara, Cara Therapeutics Stock |
Competitors | GlycoMimetics, Idera Pharmaceuticals, Leap Therapeutics, Otonomy, Inc, Visterra Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Cara Therapeutics employee's phone or email?
The Cara Therapeutics annual revenue was $13 million in 2024.
107 people are employed at Cara Therapeutics.
Cara Therapeutics is based in Stamford, Connecticut.
The NAICS codes for Cara Therapeutics are [3254, 32541, 325, 32].
The SIC codes for Cara Therapeutics are [28, 283].